Sensitivity to Neutralizing Antibodies and Resistance to Type I Interferons in SARS-CoV-2 R.1 Lineage Variants, Canada

Jacob, Rajesh Abraham; Zhang, Ali; Ajoge, Hannah O.; D'Agostino, Michael R.; Nirmalarajah, Kuganya; Shigayeva, Altynay; Demian, Wael L.; Baker, Sheridan J.C.; Derakhshani, Hooman; Rossi, Laura; Nasir, Jalees A.; Panousis, Emily M.; Draia, Ahmed N.; Vermeiren, Christie; Gilchrist, Jodi; Smieja, Nicole; Bulir, David; Smieja, Marek; Surette, Michael G.; McArthur, Andrew G.; McGeer, Allison J.; Mubareka, Samira; Banerjee, Arinjay; Miller, Matthew S.; Mossman, Karen

doi:10.3201/eid2907.230198

i

Sensitivity to Neutralizing Antibodies and Resistance to Type I Interferons in SARS-CoV-2 R.1 Lineage Variants, Canada

Supporting Files

7 2023
By Jacob, Rajesh Abraham ; Zhang, Ali ; Ajoge, Hannah O. ; ...

File Language:

English

Details

Alternative Title:

Emerg Infect Dis
Personal Author:

Jacob, Rajesh Abraham ; Zhang, Ali ; Ajoge, Hannah O. ; D'Agostino, Michael R. ; Nirmalarajah, Kuganya ; Shigayeva, Altynay ; Demian, Wael L. ; Baker, Sheridan J.C. ; Derakhshani, Hooman ; Rossi, Laura ; Nasir, Jalees A. ; Panousis, Emily M. ; Draia, Ahmed N. ; Vermeiren, Christie ; Gilchrist, Jodi ; Smieja, Nicole ; Bulir, David ; Smieja, Marek ; Surette, Michael G. ; McArthur, Andrew G. ; McGeer, Allison J. ; Mubareka, Samira ; Banerjee, Arinjay ; Miller, Matthew S. ; Mossman, Karen
Description:

Isolating and characterizing emerging SARS-CoV-2 variants is key to understanding virus pathogenesis. In this study, we isolated samples of the SARS-CoV-2 R.1 lineage, categorized as a variant under monitoring by the World Health Organization, and evaluated their sensitivity to neutralizing antibodies and type I interferons. We used convalescent serum samples from persons in Canada infected either with ancestral virus (wave 1) or the B.1.1.7 (Alpha) variant of concern (wave 3) for testing neutralization sensitivity. The R.1 isolates were potently neutralized by both the wave 1 and wave 3 convalescent serum samples, unlike the B.1.351 (Beta) variant of concern. Of note, the R.1 variant was significantly more resistant to type I interferons (IFN-α/β) than was the ancestral isolate. Our study demonstrates that the R.1 variant retained sensitivity to neutralizing antibodies but evolved resistance to type I interferons. This critical driving force will influence the trajectory of the pandemic.
Subjects:

Antibodies, Neutralizing Antibodies, Viral COVID-19 COVID-19 Serotherapy Humans Interferon Type I SARS-CoV-2 Spike Glycoprotein, Coronavirus
Source:

Emerg Infect Dis. 2023; 29(7):1386-1396
Pubmed ID:

37308158
Pubmed Central ID:

PMC10310370
Document Type:

Journal Article
Funding:

439999/CIHRCanada/
Place as Subject:

Canada
Volume:

29
Issue:

7
Collection(s):

Emerging Infectious Diseases
Main Document Checksum:

urn:sha256:d00d6a95b9e55beb3ce5333da51acea7efa90cbcaf5bec0a39eb6110e4fa8117
Download URL:

https://stacks.cdc.gov/view/cdc/130821/cdc_130821_DS1.pdf
File Type:

[PDF - 3.44 MB ]

File Language:

English

ON THIS PAGE

Details Supporting Files

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.

As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.